Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification

Annual Review of Medicine - Tập 67 Số 1 - Trang 59-72 - 2016
Krishna V. Komanduri1, Ross L. Levine2
1Adult Stem Cell Transplant Program and Department of Medicine, University of Miami Sylvester Cancer Center, Miami, Florida 33136;
2Human Oncology and Pathogenesis Program; and Leukemia Service, Department of Medicine; Memorial Sloan-Kettering Cancer Center, New York, NY 10065

Tóm tắt

The diagnosis and risk stratification of acute myeloid leukemia (AML) primarily rely on morphologic analysis and assessment of karyotype by chromosome banding analysis. For decades, standard AML induction therapy has utilized the combination of anthracyclines and cytarabine. Despite the use of postremission therapy, less than half of patients with AML will be cured of their disease. Allogeneic hematopoietic stem cell transplantation combines cytoreductive chemotherapy with adoptive immunotherapy and may cure patients who fail chemotherapy alone. Recent advances in next-generation sequencing have yielded important insights into the molecular landscape of AML with normal karyotype. Integrated prognostic models incorporating somatic mutation analyses may outperform prediction based on conventional clinical and cytogenetic factors alone. We review the evolution of risk profiling of AML from the cytogenetic to molecular era and describe the implications for AML diagnosis and postremission therapy.

Từ khóa


Tài liệu tham khảo

Cullen P, 1811, Edinb. Med. Surg. J., 7, 169

2. Velpeau A. 1825. Altération du sang. Arch. Gén. Med. 462–63

Virchow R, 1845, Frorieps Notizen., 36, 151

10.1016/j.leukres.2011.09.028

Mukherjee S, 2010, The Emperor of All Maladies: A Biography of Cancer

10.1200/JCO.1988.6.4.583

10.1016/S0140-6736(84)91350-3

10.1182/blood.V79.8.1924.1924

10.1056/NEJM199410063311402

10.1056/NEJM199812033392301

10.1182/blood.V80.12.2977.2977

10.1111/j.1365-2141.1992.tb08203.x

10.1056/NEJMoa0904544

10.1056/NEJMp078166

10.1016/S0140-6736(84)92009-9

10.1136/bmj.2.4993.626

10.1084/jem.128.4.801

10.1084/jem.128.4.821

10.1084/jem.2011fta

10.1056/NEJM195709122571102

10.1182/blood.V75.3.555.555

10.1200/JCO.1997.15.2.433

10.1182/blood.V97.3.631

10.1182/blood-2003-11-3750

10.1182/blood-2008-04-097931

10.1182/blood-2012-03-417808

10.1182/blood.V92.7.2322

10.1016/0165-4608(87)90216-0

Keating MJ, 1988, Leukemia, 2, 403

10.1182/blood-2002-03-0772

10.1182/blood.V96.13.4075

10.1182/blood-2006-04-014324

10.1182/blood-2009-11-254441

10.1001/jama.2009.813

10.1056/NEJMoa074306

10.1182/blood-2009-07-235358

10.1038/nature07485

10.1056/NEJMoa1112304

10.1056/NEJMoa1301689

10.3324/haematol.2011.051581

10.1002/cncr.25500

10.1002/cncr.24198

10.1182/blood-2012-12-476218

10.1038/nm.3788

10.1016/j.ccell.2015.03.009

10.1182/blood-2014-06-582809

10.1126/science.aaa0314

10.1038/sj.leu.2401773

10.1016/j.ccell.2015.02.016

10.1038/nm.3733

10.1056/NEJMoa1408617

10.1056/NEJMoa1409405

10.1182/blood-2014-11-610543

Thông tin
Thông tin xuất bản

Annual Review of Medicine

Tập 67 Số 1

59-72

Thông tin tác giả